Positions

Instructor in the Department of Medicine in the School of Medicine

2020 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2022 School of Medicine

Education

D.O., New York Institute of Technology, College of Osteopathic Medicine 2001

2001 New York Institute of Technology, College of Osteopathic Medicine

Residency, Penn State Milton S. Hershey Medical Center, INTERNAL MEDICINE 2002 - 2005

2005 Penn State Milton S. Hershey Medical Center

Fellowship, Yale University, MEDICAL ONCOLOGY 2006 - 2009

2009 Yale University

Clinical Trials

Synthekine STK-012 (Solid Tumors)

Xencor_XmAb819-01 (Clear Cell Renal Cell Carcinoma)

Phase 2 Study of Adjuvant V940 and Pembrolizumab in Muscle-invasive Urothelial Carcinoma

Tyra SURF-301: Phase 1/2 study for patients with urothelial carcinoma and an FGFR3 alteration

AMG 355_20220028 (Solid Tumors)

Load More

Publications, Grants & Awards

• Grants (19)
• Academics Articles (204)
• Conference Pages (25)
• Book Sections (3)

Showing 1 - 5 of 19

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

2025-2030Amgen, Inc.

A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcino

2024-2029Merck Sharp & Dohme LLC.

Xencor: ENPP3 BiTe study for ccRCC

2023-2028Xencor, Inc

BionNTech BNT142-01 (CLDN6+ solid tumors)

2023-2028BioNTech SE

Tyra-Surf-301

2023-2028Tyra Biosciences, Inc.

DCI Centers, Cancer Types & Labs

Center for Prostate and Urologic Cancers

Offices & Contact

905 S LaSalle St
Durham, NC
27710